In RA patients, MTX treatment increases the expression of lincRNA-p21 and decreases the level of p65 (RelA) phosphorylation compared with untreated RA patients (86), Interestingly, the basal levels of lincRNA-p21RA is reduced, while basal levels of RelA increased in RA patients (86). This evidence concerns the gene HRAS and rheumatoid arthritis.